| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Articles |
From the Mayo Clinic and Foundation, Rochester, Minn (W.A.J., C.M., B.P.S., D.M.M., M.M.R.); and Physiology and Biophysics Unit, University of Muenster, Muenster, Germany (J.K., W.A.L.).
Correspondence to Margaret M. Redfield, MD, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905. E-mail redfield.margaret{at}mayo.edu
Received January 23, 2008; accepted June 19, 2008.
| Abstract |
|---|
|
|
|---|
Methods and Results— We characterized titin isoform expression and extracellular matrix in all 4 cardiac chambers and the left ventricular (LV) epicardium and endocardium in normal dogs (n=6) and those with HF (n=6) due to tachypacing and characterized functional implications at the LV myofiber and chamber level. Recognizing the potential for uncoupling of the extracellular matrix and cardiomyocyte in tachypacing, myocardial natriuretic peptide production, a molecular marker of stretch-regulated responses, was also assessed. All chambers were dilated in HF, but the extracellular matrix was not increased. HF dogs had markedly lower N2BA in the atria and right ventricle. In failing LVs, N2BA was decreased only in the epicardium, where myofiber passive stiffness was increased. However, LV chamber mechanics were driven by the marked LV dilatation, with no increase in LV diastolic stiffness. Natriuretic peptide concentrations increased markedly in the endocardium in relation to increases in LV wall stress.
Conclusions— Tachypacing HF is characterized by decreases in compliant titin isoform expression in the atria, right ventricle, and LV epicardium. However, LV chamber mechanics are principally determined by geometric and extracellular matrix changes rather than titin-based myofiber stiffness in this model. Stretch-regulated myocardial responses (natriuretic peptide production) appeared intact, suggesting that the mechanotransduction role of titin was not impaired in HF.
Key Words: diastole heart failure mechanics remodeling
| Introduction |
|---|
|
|
|---|
Clinical Perspective 199
Titin is a giant sarcomeric protein that exists in the heart in 2 isoforms coexpressed at the level of the sarcomere: the shorter, stiffer N2B and various longer, more compliant N2BA isoforms. Differential expression of these isoforms is related to alternate gene splicing, influences passive stiffness of the sarcomere, and, along with geometric changes, hypertrophy, and the ECM, may contribute to myocardial and chamber mechanics in all cardiac chambers.9,10 Titin and titin-associated proteins may play a pivotal role in mechanotransduction in the heart by regulating the bidirectional interaction among the wall stress, the ECM, and the sarcomere.9 Indeed, defects in Z-disk–based mechanotransduction involving Z-disk–based binding partners of titin are associated with an inability to upregulate natriuretic peptide (NP) production in response to stretch in vitro.11
Mechanisms regulating differential titin isoform expression and the role of these isoform changes in influencing cardiac function in disease states are not well defined. To date, studies of titin isoform changes in chronic human cardiomyopathy, including DCM12–14 and experimental TRCM,15,16 are few and have yielded somewhat counterintuitive findings. Further, understanding of the influence of titin isoform–mediated changes in sarcomeric stiffness on myofiber and chamber mechanics is complicated by interaction with changes in the quantity or character of the ECM, hypertrophy, and altered chamber geometry, variables that may be coregulated by factors influencing titin isoform expression.
The objectives of the current study were to characterize titin isoform expression, hypertrophy, and ECM changes in all cardiac chambers and in the LV epicardium and endocardium in normal and TRCM canine hearts to characterize the functional implications of these changes at the LV myofiber and chamber level and to examine the relationship among wall stress, titin isoform changes, and ECM remodeling. Recognizing the putative roles of titin and titin isoform changes to sense and compensate for increases in ECM-based stiffness9,12–14 and the potential for uncoupling of the ECM and cardiomyocyte in TRCM, we also determined whether increases in wall stress were associated with increases in NP production, a molecular marker of stretch-regulated responses.
| Methods |
|---|
|
|
|---|
HF Model
Under general anesthesia (ketamine, 10 mg/kg; diazepam, 0.5 mg/kg; and isoflurane, 0.5 to 2.5%), a modified, programmable cardiac pacemaker and a permanent screw-in right ventricular epicardial lead were placed through a left thoracotomy as previously described.6 After a 2-week recovery period, the pacemaker was programmed to 180 bpm for 10 days, after which the pacing rate was increased at 7-day intervals sequentially to 200, 210, 220, and 240 bpm as previously described.6,7
Echocardiography
All dogs underwent 2D guided M-mode echocardiography in the conscious state and with pacing suspended briefly (HF dogs) for measurement of LV internal dimension and wall thickness in systole and diastole and left atrial (LA) area and volume as previously described.17 Venous blood was drawn for hormone analysis.
Hemodynamic Study
In HF dogs, the pacemaker was turned off immediately before the hemodynamic study. Animals were anesthetized with fentanyl (0.25 mg/kg bolus, then 0.18 mg/kg per hour) and midazolam (0.75 mg/kg bolus, then 0.59 mg/kg per hour) and ventilated with supplemental oxygen. The heart was exposed via a sternotomy and stabilized in a pericardial cradle. Animals were instrumented with a high-fidelity micromanometer catheter in the LV, short- and long-axis endocardial piezoelectric crystals, pneumonic inferior and superior vena cava occluders, and an atrial pacing wire. Animals were atrial paced at 10 to 20 bpm above sinus rate. Steady-state data were obtained. A 500-mL bolus of normal saline was then given to ensure that the end-diastolic pressure (EDP) and end-diastolic volume (EDV) data during vena cava occlusion would span a range reflecting the entire curvilinear end-diastolic pressure-volume relationship (EDPVR). Steady-state data before and after volume expansion were collected. Data during vena cava occlusion were collected immediately after the volume expansion to define the end-systolic pressure-volume relationship (ESPVR) and the EDPVR. Animals were euthanized, and the heart was harvested. The LV, LA, right ventricle (RV), and right atrium were separated and weighed, adding the ventricular and atrial septum to the LV and LA, respectively. The LV samples were bisected to provide equal endocardial and epicardial sections. All tissues were flash frozen in liquid nitrogen and stored at –80°C, whereas other sections were immediately placed in formalin and paraffin embedded for staining and histological analysis.
Hemodynamic Analysis
Digital data were acquired at 4-ms intervals and analyzed using customized software (Sonometrics, London, Canada). To characterize the EDPVR, EDP, and EDV points obtained from multiple beats during vena cava, occlusion were fit to the monoexponential equation EDP=
·eβ·EDV, where
is the curve-fitting constant, and β is the stiffness coefficient using least-squares nonlinear regression.18 To reflect the combined effects of diastolic properties and LV remodeling and to account for the covariance between
and β, a measure of LV capacitance was calculated, EDV20 (log[20/
]/β), or LV EDV at a theoretical pressure of 20 mm|Hg. β was normalized for wall volume (Vw; βNormalized=βxVw) as previously described.18 The LV midwall stress (
, at end systole and end diastole) was estimated using the LV pressure, LV cavity volume, and Vw in a spherical model, and the dimensionless myocardial stiffness index (
) was calculated from the EDPVR data as previously described.18 Similar methods were used to calculate end-diastolic LA midwall stress using echo-derived LA volume, LA wall volume, and LV EDP. The ESPVR was characterized as end-systolic pressure=Ees (ESV–V0), where Ees is end-systolic elastance, ESV is end-systolic volume, and V0 is the x intercept of the extrapolated ESPVR.18
Tissue Analysis
Plasma and LV atrial and canine brain NP concentrations were measured by radio-immunoassay, as previously described, with tissue concentrations normalized to protein concentration measured by the Lowry method.19,20 Total collagen content in cardiac tissue was quantified using the hydroxyproline assay21 and indexed to tissue weight. LV and LA samples were stained with picrosirus red for measurement of collagen volume fraction using quantitative histomorphometry as previously described.21 All analyses on LV were performed in endocardial and epicardial tissues, and as the tissue samples were equally bisected, endocardial and epicardial values were averaged for overall LV data.
Titin Isoform Composition and Myofiber Stiffness
Tissue samples were processed and loaded onto a 2% sodium dodecyl sulfate-polyacrylamide gel to measure relative concentrations of the titin isoforms N2B and N2BA as previously described.13,14 Mean titin isoform composition was obtained by averaging densitometry data for at least 10 gel lanes per tissue type. Passive tension of isolated, Triton X-100–skinned, myofiber bundles (diameter, 200 to 300 µm; length, 2.5 to 3.0 mm) was determined as previously described.13 Sarcomere length was measured by laser diffractometry.13 The means of 9 individual fiber measurements on epicardial and endocardial samples from 2 dogs in each group were averaged.
Statistical Analysis
Results are presented as mean±SD. Given the small number of dogs and the large variation, groups were compared using the Wilcoxon rank-sum nonparametric test, the probability values of which were reported in the tables. Student t test was also performed and yielded similar statistical significance as the Wilcoxon test. Statistical significance was set at a probability value of <0.05. The relationship between myofiber tension (normalized to fiber area) and sarcomere length was modeled as a polynomial regression as previously described13 and differences between groups were compared by ANOVA.
| Results |
|---|
|
|
|---|
) was lower in HF.
|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Experimental TRCM
Although different types of human and experimental DCM share many phenotypic characteristics, genetic, myocardial, and chamber characteristics in human or experimental DCM may vary according to etiology and duration.22–25 Previous studies in the TRCM model have reported LV dilatation and systolic dysfunction similar to that reported here.1–7 The particular pacing protocol used in the current study is unique in the progressive nature of the tachypacing insult, a variation that seems to result in mild hypertrophy not seen in other studies that use a constant high pacing rate.6,7
Assessment of myocardial and LV chamber passive diastolic properties in TRCM have been more variably described. Neumann et al26 reported marked increases in LV diastolic stiffness in conscious dogs with TRCM. However, several other studies in TRCM consistently describe a rightward shift without an increase (or with an actual decrease) in the steepness of the EDPVR or in myocardial or chamber diastolic stiffness parameters, findings consistent with those of the current study.3,5,27,28
In terms of ECM changes, consistent with the current findings, several studies have documented no change5,26,29 or slight decreases3,4,28 in collagen, depending on the method used to assess collagen and the sampling site. Spinale et al also reported that collagen cross-linking is decreased in TRCM and that types I and III collagen mRNA expression were unchanged.4 Importantly, although not assessed here, several groups have reported loss of the collagen weave connecting myocytes to each other,3,30 with disruption of the lateral sarcomere alignment and Z-line expansion4,8,30 in TRCM. Further, myocytes isolated from TRCM hearts display marked reduction in attachment to constituents of the ECM basement membrane.4,8 These findings suggest that TRCM may be characterized by fundamental defects in the coupling of the ECM to the sarcomere. Although this defect is thought to contribute to the dilatation and systolic dysfunction in the model, it could also have implications for titin-based mechanosensing and even for the stimulus for titin isoform changes. Indeed, altered mechanical feedback between the matrix and the myocyte likely affects titin isoform composition.31
Titin Isoforms in Experimental and Human DCM
Insight into the significance of titin isoform changes in cardiac disease is complicated by developmental and possible age-related changes, variability among species, chamber and transmural heterogeneity, and marked functional alterations with titin phosphorylation status.9,10,32–34 It is also impossible to determine whether the titin isoform changes observed in this experiment are solely related to HF with increased wall stress or whether tachycardia itself is contributory. In fact, smaller species with a higher heart rate have been shown to have a much lower N2BA:N2B ratio.32 To date, all factors regulating alternative splicing and differential isoform expression remain unclear, but a recent study suggests that hormonal (thyroid [T3], angiotensin) as well as mechanical factors may influence isoform changes from the fetal (more N2BA) to the adult (more N2B) phenotype through PI3K/Akt-dependent signaling.31 In humans with advanced HF due to ischemic or nonischemic DCM, LV samples were shown to have an increased cardiac N2BA:N2B ratio, which suggests reversion to a fetal phenotype12–14 as well as increases in total collagen and increases in the ratio of type I to type II collagen.35,36 Experimental evidence suggested an inverse relationship between collagen stiffness and titin stiffness in chronic human end-stage cardiomyopathy, including DCM,12–14 as well as in myocardium of a hypothyroid rat model.37 In the study of Nagueh et al12 in human DCM, decreases in relative N2BA expression correlated with worse LV diastolic function as assessed by echocardiography.
In dogs with TRCM (2 weeks of tachypacing), Bell et al15 demonstrated a lower-than-normal N2BA:N2B ratio in the epicardium but unchanged titin isoform composition in midwall segments and an increased N2BA:N2B ratio in the endocardium; this, the transmural gradient tended to be more prominent in TRCM dogs. Wu et al16 observed a lower N2BA:N2B ratio in the midmyocardial segment in dogs with TRCM (4 weeks of tachypacing), a finding associated with increases in ex vivo, midmyocardial myofiber passive stiffness. These findings are not disparate with our own. However, Wu et al also reported that collagen-based muscle stiffness determined in KCl/KI-treated myofibers was increased and speculated that increased collagen-based and titin-based stiffness contribute to increases in LV diastolic stiffness in TRCM.16 However, neither LV diastolic properties nor ECM changes were measured.
We confirm the findings of Wu and Bell, as we found a decrease in the N2BA:N2B ratio in the epicardium in TRCM but extend their findings by demonstrating that this change occurred in all 4 cardiac chambers and, more significantly, in the thinner-walled chambers. More importantly, by assessing the ECM and LV diastolic properties concomitantly with titin isoform changes, we draw different conclusions regarding the functional implications of the titin isoform changes observed in these 3 studies. First, our findings and those of several other groups suggest that LV chamber and myocardial diastolic stiffness is not increased and is indeed decreased in TRCM in the setting of marked dilatation as noted earlier. Thus, as acknowledged by Wu et al,16 other remodeling changes may dissociate changes in sarcomeric passive diastolic stiffness from chamber and even global myocardial stiffness. Second, we and others (as noted earlier) have found no increase but, if anything, a trend toward decreases in ECM content and no evidence of changes in collagen character, which could explain increases in collagen-based stiffness in TRCM, consistent with the findings with regard to chamber and myocardial stiffness seen here and by others as noted earlier.
With regard to a potential role for uncoupling of the ECM and the sarcomere in TRCM in contributing to differences in titin-based mechanical signaling in human DCM and experimental TRCM, we did not find evidence of a loss of mechanotransduction (at least in the endocardial layers), as increases in NP production in the endocardium were intact and were related to LV diastolic wall stress. Increases in NP production by the LV myocardium occur in response to wall stress, and a transmural difference with greater NP in the endocardium has been reported in humans with end-stage HF due to ischemic or nonischemic DCM38 where total NP content, as well as the endocardial to epicardial gradient, decreased with unloading of the LV with a ventricular assist device. The Z-disk mechanosensor involves titin, telethonin, and muscle-specific LIM protein. Disruption of this complex in a muscle-specific MLP protein–null mouse model resulted in DCM. In neonatal cardiomyocytes cultured from muscle-specific LIM protein–null mice, loss of upregulation of BNP in response to stretch, but not pharmacological stimulation, was observed.11 Thus, the preservation of NP activation in the endocardium in TRCM suggests that the stress-sensing function of the cardiomyocyte is intact. Although NP production can also be upregulated because of biochemical pathways, NP production correlated with wall stress and was not increased significantly in the epicardium, suggesting that the upregulation was not primarily hormonally mediated. Although stress is expected to increase in both epicardial and endocardial layers in HF, there is probably an exaggerated increase in stress in the endocardium compared with that in the epicardium,39 leading to more prominent changes in endocardial versus epicardial NP (especially that the relationship between stress and NP production may be exponential rather than linear, as suggested by Figure 3). The NP increase in the epicardium may have been too small in this small sample size (n=6) to be statistically significant. In fact, there was a positive correlation between wall stress and both endocardial and epicardial log (BNP).
In the absence of unique disruption of stress sensing, the mechanism for differential changes in titin isoform expression in human DCM and experimental TRCM remains unclear, as both human HF and this model are characterized by increases in wall stress, activation of the renin-angiotensin-aldosterone system,7 and alterations in thyroid function consistent with a "euthyroid sick" state.40 As titin composition is altered via the induction of the PI3K/Akt pathway during heart development,31 there is a possibility that one or more of the many triggers of this pathway activate the transition toward increased N2B proportions in TRCM.
It is of note that the atria and RV showed dramatic reduction in the more compliant isoform expression. Although both ventricles are subjected to tachycardia stress, ventricular-atrial conduction may not be 1:1, and the higher ventricular filling pressures may expose the atria to a more conventional pressure overload stress. Although not assessed, atrial chamber properties may be more sensitive to increases in titin-based stiffness, and these changes may be important in the pathophysiology of HF, as all cardiac chambers contribute to the final homeostasis.
Limitations
Atrial and RV myofiber and chamber mechanics were not assessed nor was collagen-based myofiber stiffness. Study of other canines with other etiologies of HF may provide insight into regulation of titin isoform changes. Tachycardia by itself, besides HF, may contribute to the titin isoform expression changes. As RV is paced first in this model, some changes observed in the atria may also be related to retrograde activation or atrioventricular dissociation with contraction against closed valves and may not fully represent what happens in other HF models. However, increases in atrial afterload because of increased ventricular diastolic pressures or contracting against a closed valve still present a similar type of stress (pressure overload) to the atria. Moreover, as heart rate may alter myocardial stiffness, it would have been interesting to define myocardial properties during tachycardia, which was not done here. Studying diastolic properties during extreme tachycardia would be challenging given the very short duration of diastole and the effect of incomplete relaxation.
| Conclusions |
|---|
|
|
|---|
| Acknowledgments |
|---|
None.
Sources of Funding
Funding for this study was provided by the National Institutes of Health (NIH HL 63281; to M.M.R.) and by the German Research Foundation (Grant Li 690/7-1; to W.A.L.)
| References |
|---|
|
|
|---|
2. Komamura K, Vatner SF [Alterations in left ventricular systolic and diastolic function in conscious dogs with pacing-induced heart failure]. Jpn Circ J. 1993; 57 (suppl 4): 1238–1240.[Medline]
3. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991; 261: H308–H318.[Medline]
4. Spinale FG, Zellner JL, Johnson WS, Eble DM, Munyer PD. Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol. 1996; 28: 1591–1608.[CrossRef][Medline]
5. Komamura K, Shannon RP, Pasipoularides A, Ihara T, Lader AS, Patrick TA, Gishop SP, Vatner SF. Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure. J Clin Invest. 1992; 89: 1825–1838.[Medline]
6. Yamamoto K, Burnett JC, Jr., Meyer LM, Sinclair L, Stevens TL, Redfield MM. Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model. Am J Physiol. 1996; 271: R1529–R1534.[Medline]
7. Stevens TL, Borgeson DD, Luchner A, Wennberg PW, Redfield MM, Burnett JJC. A modified model of tachycardia-induced cardiomyopathy: insights into humoral and renal adaptations. In: Pathophysiology of Tachycardia-Induced Heart Failure. New York: Futura; 1996.
8. Zellner JL, Spinale FG, Eble DM, Hewett KW, Crawford FA, Jr. Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. Circ Res. 1991; 69: 590–600.
9. Linke WA. Sense and stretchability: the role of titin and titin-associated proteins in myocardioal stress-sensing and mechanical dysfunction. Cardiovasc Res. 2008; 77: 637–648.
10. LeWinter MM, Wu Y, Labeit S, Granzier H. Cardiac titin: structure, functions and role in disease. Clin Chim Acta. 2007; 375: 1–9.[CrossRef][Medline]
11. Knoll R, Hoshijima M, Hoffman HM, Person V, Lorenzen-Schmidt I, Bang ML, Hayashi T, Shiga N, Yasukawa H, Schaper W, McKenna W, Yokoyama M, Schork NJ, Omens JH, McCulloch AD, Kimura A, Gregorio CC, Poller W, Schaper J, Schultheiss HP, Chien KR. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 2002; 111: 943–955.[CrossRef][Medline]
12. Nagueh SF, Shah G, Wu Y, Torre-Amione G, King NM, Lahmers S, Witt CC, Becker K, Labeit S, Granzier HL. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation. 2004; 110: 155–162.
13. Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, del Monte F, Hajjar RJ, Linke WA. Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res. 2004; 95: 708–716.
14. Neagoe C, Kulke M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, Linke WA. Titin isoform switch in ischemic human heart disease. Circulation. 2002; 106: 1333–1341.
15. Bell SP, Nyland L, Tischler MD, McNabb M, Granzier H, LeWinter MM. Alterations in the determinants of diastolic suction during pacing tachycardia. Circ Res. 2000; 87: 235–240.
16. Wu Y, Bell SP, Trombitas K, Witt CC, Labeit S, LeWinter MM, Granzier H. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation. 2002; 106: 1384–1349.
17. Maniu CV, Patel JB, Reuter DG, Meyer DM, Edwards WD, Rihal CS, Redfield MM. Acute and chronic reduction of functional mitral regurgitation in experimental heart failure by percutaneous mitral annuloplasty. J Am Coll Cardiol. 2004; 44: 1652–1661.
18. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005; 289: H501–H512.
19. Hart CY, Meyer DM, Tazelaar HD, Grande JP, Burnett JC, Jr, Housmans PR, Redfield MM. Load versus humoral activation in the genesis of early hypertensive heart disease. Circulation. 2001; 104: 215–220.
20. Munagala VK, Hart CY, Burnett JC, Jr., Meyer DM, Redfield MM. Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure. Circulation. 2005; 111: 1128–1135.
21. Shapiro BP, Lam CS, Patel JB, Mohammed SF, Kruger M, Meyer DM, Linke WA, Redfield MM. Acute and chronic ventricular-arterial coupling in systole and diastole: insights from an elderly hypertensive model. Hypertension. 2007; 50: 503–511.
22. Yarbrough WM, Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Escobar GP, Joffs C, Lucas DG, Crawford FA, Jr., Spinale FG. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003; 125: 602–610.
23. Zile MR, Tomita M, Nakano K, Mirsky I, Usher B, Lindroth J, Carabello BA. Effects of left ventricular volume overload produced by mitral regurgitation on diastolic function. Am J Physiol. 1991; 261: H1471–H1480.[Medline]
24. Gaasch WH, Cole JS, Quinones MA, Alexander JK. Dynamic determinants of letf ventricular diastolic pressure-volume relations in man. Circulation. 1975; 51: 3173–23.
25. Williams RE, Kass DA, Kawagoe Y, Pak P, Tunin RS, Shah R, Hwang A, Feldman AM. Endomyocardial gene expression during development of pacing tachycardia-induced heart failure in the dog. Circ Res. 1994; 75: 615–623.
26. Neumann T, Vollmer A, Schaffner T, Hess OM, Heusch G. Diastolic dysfunction and collagen structure in canine pacing-induced heart failure. J Mol Cell Cardiol. 1999; 31: 179–192.[CrossRef][Medline]
27. Solomon SB, Nikolic SD, Glantz SA, Yellin EL. Left ventricular diastolic function of remodeled myocardium in dogs with pacing-induced heart failure. Am J Physiol. 1998; 274: H945–H954.[Medline]
28. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 1999; 85: 364–376.
29. Wilson JR, Douglas P, Hickey WF, Lanoce V, Ferraro N, Muhammad A, Reichek N. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation. 1987; 75: 857–867.
30. Komamura K, Shannon RP, Ihara T, Shen YT, Mirsky I, Bishop SP, Vatner SF. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol. 1993; 265: H1119–H1131.[Medline]
31. Kruger M, Sachse C, Zimmermann WH, Eschenhagen T, Klede S, Linke WA. Thyroid hormone regulates developmental titin isoform transitions via the PI3K/AKT pathway. Circ Res. 2008: 102: 439–447.
32. Cazorla O, Freiburg A, Helmes M, Centner T, McNabb M, Wu Y, Trombitas K, Labeit S, Granzier H. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res. 2000; 86: 59–67.
33. Wu Y, Cazorla O, Labeit D, Labeit S, Granzier H. Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol. 2000; 32: 2151–2162.[CrossRef][Medline]
34. Kruger M, Kohl T, Linke WA. Developmental changes in passive stiffness and myofilament Ca2+ sensitivity due to titin and troponin-I isoform switching are not critically triggered by birth. Am J Physiol Heart Circ Physiol. 2006; 291: H496–H506.
35. Marijianowski MM, Teeling P, Mann J, Becker AE. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol. 1995; 25: 1263–1272.[Abstract]
36. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF, Jr. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 1996; 148: 1639–1648.[Abstract]
37. Wu Y, Peng J, Campbell KB, Labeit S, Granzier H. Hypothyroidism leads to increased collagen-based stiffness and re-expression of large cardiac titin isoforms with high compliance. J Mol Cell Cardiol. 2007; 42: 186–195.[CrossRef][Medline]
38. Altemose GT, Gritsus V, Jeevanandam V, Goldman B, Margulies KB. Altered myocardial phenotype after mechanical support in human beings with advanced cardiomyopathy. J Heart Lung Transplant. 1997; 16: 765–773.[Medline]
39. Yin FC. Ventricular wall stress. Circ Res. 1981; 49: 829–842.
40. Panciera DL, Refsal KR. Thyroid function in dogs with spontaneous and induced congestive heart failure. Can J Vet Res. 1994; 58: 157–162.[Medline]
| Footnotes |
|---|
This article has been cited by other articles:
![]() |
A. Borbely, I. Falcao-Pires, L. van Heerebeek, N. Hamdani, I. Edes, C. Gavina, A. F. Leite-Moreira, J. G.F. Bronzwaer, Z. Papp, J. van der Velden, et al. Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium Circ. Res., March 27, 2009; 104(6): 780 - 786. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Home | Subscriptions | Archives | Feedback | Authors | Help | Circulation Journals Home | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |